299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
15 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04468100
(ClinicalTrials.gov)
August 30, 20178/7/2020Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic FibrosisA Multicenter Prospective Randomized Comparative Study of Pharmacokinetics, Clinical Efficacy and Safety of Tigerase® (JSC GENERIUM, Russia) vs. Pulmozyme® (Hoffmann-La Roche, Switzerland) as Part of Complex Therapy in Patients With Cystic FibrosisCystic Fibrosis;FibrosisBiological: Tigerase®;Biological: Pulmozyme®AO GENERIUMNULLCompleted18 YearsN/AAll100Phase 3Russian Federation
2NCT02722122
(ClinicalTrials.gov)
May 201623/3/2016Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®Cystic FibrosisDrug: AIR DNase™ProtalixNULLRecruiting12 YearsN/ABoth15Phase 2Israel
3NCT01155752
(ClinicalTrials.gov)
July 201325/6/2010Pulmozyme in Cystic Fibrosis With SinusitisZ4770s, Use of Recombinant Human DNASE in Cystic Fibrosis Patients With Chronic Sinusitis to Prevent Acute Sinusitis Exacerbations and Improve Symptoms and Outcomes - A Pilot StudySinusitis;Cystic FibrosisDrug: Pulmozyme single use ampule;Drug: placeboMilton S. Hershey Medical CenterGenentech, Inc.Withdrawn12 Years65 YearsAll0Phase 3United States
4NCT01712334
(ClinicalTrials.gov)
December 201219/10/2012A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer SystemCystic FibrosisDrug: dornase alfa [Pulmozyme®]Genentech, Inc.NULLCompleted6 YearsN/AAll99Phase 4United States
5NCT00843817
(ClinicalTrials.gov)
April 200912/2/2009RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis SputumRhDNase Effect on Biodistribution of PMN Serine Proteases in Cystic Fibrosis SputumCystic FibrosisDrug: PulmozymeUniversity Hospital, ToursNULLCompleted18 YearsN/AAll15Phase 4France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00680316
(ClinicalTrials.gov)
June 200816/5/2008A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic FibrosisA Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic FibrosisCystic FibrosisDrug: Dornase alfa;Drug: PlaceboGenentech, Inc.NULLTerminated3 Years5 YearsAll3Phase 4United States
7NCT00534079
(ClinicalTrials.gov)
September 200721/9/2007Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical StudyCystic Fibrosis;RhinosinusitisDrug: Dornase alfa (Pulmozyme);Drug: isotonic salineUniversity of JenaNULLCompleted5 YearsN/ABoth23Phase 3Germany
8NCT00434278
(ClinicalTrials.gov)
March 200711/2/2007A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung DiseaseCystic FibrosisDrug: Dornase alfa;Drug: placeboGenentech, Inc.NULLTerminated14 YearsN/AAll27Phase 4United States
9NCT00416182
(ClinicalTrials.gov)
December 200626/12/2006Nasally Delivered Pulmozyme for Sinusitis in Cystic FibrosisThe Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot StudySinusitis;Cystic FibrosisDrug: Pulmozyme (dornase alfa);Drug: PlaceboUniversity of VermontGenentech, Inc.Completed5 YearsN/AAll16Phase 2United States
10NCT00265434
(ClinicalTrials.gov)
December 200513/12/2005Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisCystic Fibrosis;Chronic RhinosinusitisDrug: PulmozymeUniversity of JenaPD Dr. Joachim Riethmöller, Tübingen;PD Dr. Assen Koitschev, Tübingen;Dr. Gerlind SchneiderCompleted5 YearsN/ABoth5Phase 3Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00117208
(ClinicalTrials.gov)
November 200530/6/2005Comparison of Inhaled Mannitol and rhDNase in Children With Cystic FibrosisA Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic FibrosisCystic FibrosisDrug: mannitol;Drug: mannitol + pulmozyme;Drug: Dornase alphaPharmaxisNULLCompleted8 Years18 YearsBoth20Phase 2United Kingdom
12NCT00179998
(ClinicalTrials.gov)
January 200510/9/2005Effectiveness of Pulmozyme in Infants With Cystic FibrosisEfficacy of Pulmozyme in Infants and Young Children With Cystic FibrosisCystic FibrosisDrug: Recombinant Human DNase (Pulmozyme);Drug: PlacebosNationwide Children's HospitalGenentech, Inc.Completed1 Month30 MonthsAll24Phase 2United States
13EUCTR2007-000935-25-NL
(EUCTR)
02/04/2007‘Peripheral targeting of inhaled rhDNase in stable CF patients.’‘Peripheral targeting of inhaled rhDNase in stable CF patients.’ Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
MedDRA version: 9.1;Classification code 10011763;Term: Cystic fibrosis lung
Trade Name: Pulmozyme (Dornase alpha)
Product Name: Pulmozyme
ErasmusMC - Sophia Children's HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Netherlands
14EUCTR2007-001548-36-DE
(EUCTR)
27/07/2009Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cfNasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf Cystic Fibrosis with chronic rhinosinusitisTrade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: Dornase alfa
Other descriptive name: recombiant human Desoxyribonuclease ( rhDNase)
University of JenaNULLNot RecruitingFemale: yes
Male: yes
16Phase 3Germany
15EUCTR2015-003537-99-Outside-EU/EEA
(EUCTR)
05/07/2016A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEBULIZER SYSTEM Cystic Fibrosis
MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: DORNASE ALFA
F. Hoffmann-La Roche AGNULLNAFemale: yes
Male: yes
80Phase 4United States